Home Cart Sign in  
Chemical Structure| 1799711-21-9 Chemical Structure| 1799711-21-9

Structure of dBET1
CAS No.: 1799711-21-9

Chemical Structure| 1799711-21-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

dBET1 is a PROTAC, consisting of a BRD4-ligand JQ-1 linkerd to a cereblon E3 ligase ligand, targeting on BET bromodomain BRD4

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of dBET1

CAS No. :1799711-21-9
Formula : C38H37ClN8O7S
M.W : 785.27
SMILES Code : O=C(NCCCCNC(COC1=CC=CC(C(N2C(CC3)C(NC3=O)=O)=O)=C1C2=O)=O)C[C@H]4C5=NN=C(C)N5C6=C(C(C)=C(C)S6)C(C7=CC=C(Cl)C=C7)=N4
MDL No. :MFCD31544503
InChI Key :LKEGXJXRNBALBV-PMCHYTPCSA-N
Pubchem ID :91799313

Safety of dBET1

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of dBET1

epigenetics

Isoform Comparison

Biological Activity

Target
  • BET

    BRD4, IC50:20 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
MV4;11 cells 250 nM 2 h Selective degradation of BET family members BRD2, BRD3 and BRD4 PMC4937790
SUM149 breast cancer cells 430 nM (EC50) 18 h Potent depletion of total BRD4 PMC4937790
MV4;11 cells 100 nM 18 h Pronounced loss of BRD4 (> 85%) PMC4937790
MDA-MB-231 cells 25 nM to 10 μM 48 h Evaluate the effect of dBET1 on protein levels of BRD4, BRD3, and BRD2. Results showed no significant degradation effect of dBET1 in MDA-MB-231 cells. PMC8480205
MDA-MB-468 cells 0.5, 1, 5 μM 12, 24, 36, 48, 72 h Evaluate the effect of dBET1 on protein levels of BRD4, BRD3, and BRD2. Results showed that dBET1 significantly reduced protein levels of BRD4 long (L) and short (S) isoforms within 12 h, but the protein levels rebounded significantly within 36 h. PMC8480205
SW480 cells 5-10 μM Evaluate the degradation effect of dBET1 on BRD4 protein, showing SW480 cells are insensitive to dBET1 PMC6888720
LS174t cells 1 μM 24 h Evaluate the degradation effect of dBET1 on BRD4 and MYC proteins, showing complete degradation of BRD4 and MYC proteins PMC6888720
LS174t cells 200 nM 2 h Evaluate the degradation effect of dBET1 on BRD4 protein, showing significant reduction of BRD4 protein within 2 h PMC6888720

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice Human MV4;11 leukemia xenograft model Intraperitoneal injection 50 mg/kg Daily for 14 days Attenuated tumor progression and decreased tumor weight PMC4937790
C57BL/6J male mice Transient focal cerebral ischemia model Intraperitoneal injection 30 mg/kg Administered at 4 and 24 hours after ischemia DBET1 significantly improved neurological deficits and reduced infarct volume after ischemic stroke, associated with reduced neuroinflammation and oxidative stress and preservation of blood-brain barrier integrity. PMC9237998

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.27mL

0.25mL

0.13mL

6.37mL

1.27mL

0.64mL

12.73mL

2.55mL

1.27mL

References

 

Historical Records

Categories